Candriam SCA’s Avadel Pharmaceuticals AVDL Stock Holding History

Candriam SCA’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-85,000	Closed	-$428K	–	812
2020 Q3	$428K	Hold	85,000	–	–	﹤0.01%	723
2020 Q2	$687K	Buy	+85,000	New	+$749K	0.01%	664
2019 Q1	–	Sell	-62,000	Closed	-$160K	–	795
2018 Q4	$160K	Hold	62,000	–	–	﹤0.01%	773
2018 Q3	$272K	Hold	62,000	–	–	﹤0.01%	762
2018 Q2	$380K	Hold	62,000	–	–	0.01%	725
2018 Q1	$452K	Hold	62,000	–	–	0.01%	688
2017 Q4	$508K	Sell	62,000 -49,000	-44%	-$459K	0.01%	674
2017 Q3	$1.17M	Hold	111,000	–	–	0.02%	546
2017 Q2	$1.22M	Hold	111,000	–	–	0.02%	544
2017 Q1	$1.07M	Buy	+111,000	New	+$1.11M	0.02%	552
2016 Q4	–	Sell	-111,000	Closed	-$1.38M	–	672
2016 Q3	$1.38M	Hold	111,000	–	–	0.03%	437
2016 Q2	$1.19M	Hold	111,000	–	–	0.03%	401
2016 Q1	$1.22M	Sell	111,000 -44,600	-29%	-$443K	0.03%	400
2015 Q4	$1.9M	Buy	155,600 +25,000	+19%	+$390K	0.05%	303
2015 Q3	$2.13M	Sell	130,600 -1,400	-1%	-$30.8K	0.05%	330
2015 Q2	$2.8M	Sell	132,000 -76,000	-37%	-$1.36M	0.06%	326
2015 Q1	$3.74M	Buy	208,000 +16,000	+8%	+$251K	0.08%	302
2014 Q4	$3.29M	Buy	+192,000	New	+$2.74M	0.07%	296

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Candriam SCA's AVDL Position: Q4 2020 in Review

Candriam SCA sold out of Avadel Pharmaceuticals (AVDL) in Q4 2020, closing a stake of 85,000 shares — an estimated $428K sold.

Candriam SCA first reported a position in AVDL in Q4 2014 and held it in 18 quarters. The position peaked at $3.74M in Q1 2015. 82 funds tracked by Wall St. Rank hold AVDL as of Q4 2020.

Candriam SCA reported no remaining Avadel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Candriam SCA sold 85,000 Avadel Pharmaceuticals shares in Q4 2020, an estimated $428K.
Candriam SCA first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 18 quarters.
Candriam SCA's Avadel Pharmaceuticals position peaked at $3.74M in Q1 2015.
82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.